Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders, with a portfolio centered on orthobiologics and spinal implant systems. The XTNT news feed on Stock Titan aggregates company-issued updates and regulatory disclosures so readers can follow how Xtant communicates its strategy, product launches, and financial performance.
Recent news releases describe Xtant’s emphasis on its core biologics business and regenerative medicine capabilities. The company has announced the commercial launch of products such as CollagenX™, a bovine collagen particulate product for surgical wound closure, and OsteoFactor Pro™, a growth factor-based biologic designed to improve bone healing across orthopedic and spine procedures. Xtant has also introduced Trivium™, a next-generation demineralized bone matrix allograft, and nanOss Strata™, a synthetic bone graft manufactured from hydroxycarbonapatite and designed to mimic human bone structure and support osteoconductivity and cellular activity.
Company news also covers strategic transactions and portfolio changes. Xtant has reported entering into, and subsequently completing, the sale of certain non-core Coflex and CoFix spinal implant assets and its Paradigm Spine GmbH international hardware business to Companion Spine entities, describing these divestitures as a way to sharpen its focus on biologics and strengthen its balance sheet.
Investors and analysts following XTNT news will find quarterly earnings announcements, including revenue trends, gross margin, net income, adjusted EBITDA, and cash flow metrics, as well as financial guidance for the year. The company also issues notices about participation in investor conferences, annual meeting details, and governance developments such as changes to its Board of Directors and amendments to equity incentive plans.
By reviewing the XTNT news stream, readers can see how Xtant presents its mission of honoring the gift of donation, its product development priorities in orthobiologics and wound closure, and the financial and strategic milestones it reports through press releases and SEC-related communications.
Xtant Medical Holdings (NYSE American: XTNT) will release its financial results for Q4 and the full year ending December 31, 2021, on March 8, 2022, before market open. CEO Sean Browne and Interim CFO Scott Neils will discuss the results in a conference call scheduled for the same day at 9:00 AM ET. Investors can access the call by dialing 877-407-6184 or internationally at 201-389-0877. A replay will be available on their website post-call.
Xtant Medical Holdings, a global medical technology company specializing in spinal disorder solutions, announced that CEO Sean Browne will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A pre-recorded presentation will be available on the company's website starting January 10, 2022, at 7:00 AM Eastern Time and will remain accessible for 30 days. Xtant focuses on designing and commercializing orthobiologics and spinal implant systems for complex spinal procedures.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has appointed Scott Neils as Interim Chief Financial Officer, effective January 3, 2022. Neils, who has 15 years of experience in public accounting and corporate finance, previously served as the Company’s Controller since August 2019. His promotion follows the tenure of Greg Jensen, who has led the finance team for nearly three years. Neils' extensive experience in finance will be pivotal for the Company as it continues to focus on surgical solutions for spinal disorders, ensuring stability during this transitional phase.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported third quarter 2021 financial results, noting a revenue of $13.8 million, a slight decrease from $14.0 million in the prior-year period. The company experienced a net loss of $1.8 million, up from a loss of $1.4 million year-over-year. Gross margin also declined to 52.2% from 66.0%, attributed to changes in sales mix and increased write-downs of excess inventory. Operating expenses rose to $8.6 million due to higher salaries and marketing costs. Xtant continues to expand its distribution network despite challenges from the COVID-19 delta variant.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will announce its Q3 financial results for the period ending September 30, 2021, on November 12, 2021, prior to market opening. A conference call featuring Sean Browne, President and CEO, and Greg Jensen, CFO, is scheduled for 9:00 AM ET the same day. Investors can listen to the call via dial-in or webcast. Xtant Medical specializes in surgical solutions for spinal disorders and offers a range of orthobiologics and spinal implant systems.
Summary not available.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that CEO Sean Browne will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. A pre-recorded presentation will be available on the company's website starting September 13, 2021, at 7:00 AM Eastern Time and will remain accessible for 90 days. Xtant Medical focuses on developing and commercializing spinal implant systems and orthobiologics for spinal fusion.
Xtant Medical Holdings, focused on surgical solutions for spinal disorders, reported a 42% revenue increase to $15.0 million for Q2 2021 compared to the previous year. The gross margin improved to 63.5% from 62.2%. The net loss shrank to $0.7 million or $0.01 per share, significantly better than the $2.5 million loss in Q2 2020. The company closed a $20 million debt refinancing and reported a Non-GAAP Adjusted EBITDA of $0.9 million. Xtant's expansion in sales force and distribution aims to enhance future growth.
Xtant Medical Holdings, Inc. (XTNT) will release its financial results for Q2 2021 on August 5, 2021, before the market opens. The conference call will be hosted by CEO Sean Browne and CFO Greg Jensen at 9:00 AM ET, providing insights into the company’s performance in the spinal disorder market. Investors can access the call via dial-in or webcast, with a replay available on their website.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will have its CEO Sean Browne present at the Canaccord Musculoskeletal Conference on May 20, 2021, at 3:00 PM ET. The presentation focuses on innovations in spinal surgery solutions. Investors can access a live webcast on the company's website. A replay will be available for 90 days post-event. Xtant Medical specializes in spinal implant systems, offering comprehensive orthobiologics for complex spine procedures.